-- On-track to initiate IND-enabling activities for Wilson's Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across its Prime Editing pipeline and platform at the upcoming European Society of Gene and Cell Therapy (ESGCT) 31s ...

Shares of Prime Medicine, Inc. (PRME) were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb (BMY) . The collaboration is aimed at developing reagents for the next generation of ex vivo T-cell therapies. Year to date, PRME's shares have lost 56.3% compared with the industry's decline of 1.2%. Image Source: Zacks Investment Research Terms of PRME's Deal With BMY Prime Medicine is deploying its proprietary gene editing techno ...

Changes are afoot at the company, and investors welcomed them. Next-generation healthcare company Prime Medicine (PRME 11.85%) was exactly what the doctor ordered for ailing portfolios on the first trading day of the week. On a company update and news of collaboration with a top healthcare business, investors piled into the gene-editing specialist and sent its share price almost 12% higher today. That compared very favorably with the 0.4% gain in the bellwether S&P 500 index. A new development deal Arguably ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday. The Dow traded down 0.55% to 42,079.06 while the NASDAQ rose 0.14% to 18,144.66. The S&P 500 also fell, dropping, 0.14% to 5,730.18. Check This Out: How To Earn $500 A Month From McCormick Stock Ahead Of Q3 Earnings Leading and Lagging Sectors Consumer staples shares jumped by 0.3% on Monday. In trading on Monday, materials shares fell by 0.6%. Top Headline The Chicago PMI rose to 46.6 in ...

On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies. Under the terms of the agreement, Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) technology. Also Read: Preclinical-Phase Firm Prime Medicine's Gene Editing Platfo ...

-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical Data from Phase 1/2 Trial in CGD Expected in 2025 While Advancing Wilson's Disease Program Toward Expected IND Application and/or CTA in 1H 2026 -- -- Today Announced Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission file number 001-41536 Prime Medicine, Inc. (Exact name of registrant as specified in its charter) Delawar ...

Financial Performance - Net loss for Q2 2024 was $55.3 million, compared to a net loss of $42.4 million in Q2 2023, indicating a 30% increase in losses[6]. - R&D expenses for Q2 2024 were $43.1 million, up from $34.6 million in Q2 2023, reflecting a 24% increase driven by pipeline advancement[5]. - G&A expenses for Q2 2024 were $12.6 million, compared to $10.7 million in Q2 2023, representing an 18% increase[5]. - Cash position as of June 30, 2024, was $176.4 million, up from $135.2 million as of December 31, 2023, showing a 30% increase[6]. - Prime Medicine's total assets as of June 30, 2024, were $259.7 million, compared to $193.9 million as of December 31, 2023[13]. - The weighted-average common shares outstanding increased to 119,188,866 in Q2 2024 from 90,467,298 in Q2 2023[14]. Clinical Development - Prime Medicine received FDA clearance to advance PM359 for chronic granulomatous disease into clinical trials, with initial clinical data expected in 2025[2]. - The company plans to establish proof-of-concept for Shielded Hematopoietic Stem Cell and Immunotherapy Pairs technology in 2024[4]. - Prime Medicine aims to initiate IND-enabling activities for at least one liver program in 2024, targeting IND or clinical trial application in H2 2025 or H1 2026[4]. - The company is advancing its differentiated CAR-T program using PASSIGE technology into lead optimization[4].

Prime Medicines (PRME) has made encouraging pipeline progress of late and investors will focus on related updates when it reports second-quarter 2024 results next month. Surprise - Reported Earnings Histor The Zacks Consensus Estimate for loss per share in the second quarter is pinned at 40 cents. | --- | --- | --- | --- | --- | |----------------------|----------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | Magnitude Consensus Estimate Trend (60 Days) | | | | | | ...

Prime Medicine, Inc.'s (PRME) shares have risen 16.4% in the past three months compared with the industry's growth of 10.9%. The stock has also outperformed the sector and the S&P 500. PRME Outperforms Industry, Sector & S&P 500 Prime Medicine is deploying its proprietary gene editing technology, Prime Editing platform, to develop a new class of differentiated one-time curative genetic therapies. While the approach is interesting, the company's ability to have sufficient cash leeway to conduct its R&D progr ...